ArticleCase reports in endocrinology2020
Dapagliflozin-Induced Acute Pancreatitis: A Case Report and Review of Literature.
Article in Case reports in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Review
- Association Between SGLT2 Inhibitors and DPP-4 Inhibitors Use and Risk of Acute Pancreatitis: Findings From Nationwide Case-Based Analyses.Diabetes, obesity & metabolism · 2026Article
- Clinical Outcomes and Complications of Basal, Bolus, and Combination Insulin Regimens in Type 2 Diabetes Mellitus: Evidence from Published Case Reports.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- Safety assessment of dapagliflozin: Real-world adverse event analysis based on the FAERS database from 2012 to 2023.Heliyon · 2024Article
- Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors and the Risk of Pancreatitis: A Case Report.Cureus · 2024Article
- Dapagliflozin-Induced Acute Pancreatitis: A Case Presentation and Review of the Literature.Cureus · 2024Article
- Empagliflozin-Associated Pancreatitis in the Setting of Hyperglycemic Hyperosmolar Syndrome.Cureus · 2024Article
- SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports.International journal of clinical pharmacy · 2022Review
- Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: Based on food and drug administration adverse event report system database.Frontiers in pharmacology · 2022Article
- Probable Dapagliflozin-Associated Acute Pancreatitis.Diabetes spectrum : a publication of the American Diabetes Association · 2022Article
- Pancreaticopleural fistula: An insidious cause of pleural effusion -case report.Journal of cardiovascular and thoracic research · 2022Article
- Safety and efficacy of pharmacologic weight loss in patients with cirrhosis.Obesity science & practice · 2021Article
- Pancreatitis in a 57-Year-Old Female Two Weeks After Initiation of Empagliflozin.AACE clinical case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are increasingly used as add-on therapy in patients with poorly controlled type 2 diabetes mellitus (T2DM). Although pancreatitis is not a known side effect of SGLT-2 inhibitors, there have been case reports of SGLT-2 inhibitor use being associated with pancreatitis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.